Further investigations are needed here: prospective studies could probably help to better assess the benefits mTOR inhibitors in the prevention of HCC recurrence after LT, but also in the treatment of recurrent HCC after transplant [32]. This evidence concerns the gene MTOR and hepatocellular carcinoma.